Table 3 Clinical benefit of using the 25-Gene PLNM-Score urine test (25 G PLNM-Score) for detecting pelvic lymph node metastasis (PLNM) in the retrospective IND-CHTN Cohort and prospective Multi-Hospital Cohort.
Positive Diagnosis | Negative Diagnosis | Total | TP Rate (%) | TN Rate (%) | FP Rate (%) | FN Rate (%) | PLND Spared (%) | PLNM Missed (%) | |
|---|---|---|---|---|---|---|---|---|---|
25 G PLNM-Score diagnosis in the IND-CHTN Cohort (n = 413) | |||||||||
PLNM | 18 | 2 | 20 | 18/18 (100%) | 393/395 (99%) | 0/18 (0%) | 2/395 (0.51%) | 395/413 (96%) | 2/395 (0.51%) |
Non-PLNM | 0 | 393 | 393 | ||||||
ISUP/Gleason grade diagnosis in the IND-CHTN Cohort (n = 413) | |||||||||
PLNM | 20 | 0 | 20 | 20/387 (5.2%) | 26/26 (100%) | 367/387 (95%) | 0/26 (0%) | 26/413 (6.3%) | 0/26 (0%) |
Non-PLNM | 367 | 26 | 393 | ||||||
Cancer stage diagnosis in the IND-CHTN Cohort (n = 413) | |||||||||
PLNM | 20 | 0 | 20 | 20/412 (4.9%) | 1/1 (100%) | 392/412 (95%) | 0/1 (0%) | 1/413 (0.24%) | 0/1 (0%) |
Non-PLNM | 392 | 1 | 393 | ||||||
25 G PLNM-Score diagnosis in the Multi-Hospital Cohort (n = 243) | |||||||||
PLNM | 33 | 2 | 35 | 33/49 (67%) | 192/194 (99%) | 16/49 (33%) | 2/194 (1%) | 194/243 (80%) | 2/194 (1%) |
Non-PLNM | 16 | 192 | 208 | ||||||
The MSKCC score diagnosis in the Multi-Hospital Cohort (n = 243) | |||||||||
PLNM | 35 | 0 | 35 | 35/207 (17%) | 36/36 (100%) | 172/207 (83%) | 0/36 (0%) | 36/243 (15%) | 0/36 (0%) |
Non-PLNM | 172 | 36 | 208 | ||||||
